Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 409 publications
Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortality.
Journal: medRxiv : the preprint server for health sciences
Published: July 10, 2026
Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).
Journal: American journal of hematology
Published: June 25, 2026
Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes.
Journal: Haematologica
Published: June 22, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution.
Journal: NEJM evidence
Published: May 26, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia.
Journal: Journal of the American Heart Association
Published: May 06, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 27, 2026
Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.
Journal: Blood cancer journal
Published: March 13, 2026
Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations.
Journal: Blood neoplasia
Published: March 09, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.
Journal: Blood cancer journal
Published: February 03, 2026
Last Updated: 09/26/2026